A detailed history of Carolinas Wealth Consulting LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Carolinas Wealth Consulting LLC holds 57 shares of VRTX stock, worth $26,509. This represents 0.0% of its overall portfolio holdings.

Number of Shares
57
Previous 113 49.56%
Holding current value
$26,509
Previous $47,000 44.68%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$392.81 - $485.53 $21,997 - $27,189
-56 Reduced 49.56%
57 $26,000
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $60,338 - $66,019
-148 Reduced 56.7%
113 $47,000
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $19,208 - $22,998
56 Added 27.32%
261 $106,000
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $34,156 - $36,608
-101 Reduced 33.01%
205 $71,000
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $23,581 - $26,393
75 Added 32.47%
306 $107,000
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $18,126 - $20,678
64 Added 38.32%
231 $72,000
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $4,857 - $5,465
-17 Reduced 9.24%
167 $48,000
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $4,928 - $5,499
-18 Reduced 8.91%
184 $53,000
Q2 2022

Aug 16, 2022

SELL
$234.96 - $292.55 $11,513 - $14,334
-49 Reduced 19.52%
202 $57,000
Q1 2022

May 17, 2022

SELL
$221.42 - $260.97 $13,063 - $15,397
-59 Reduced 19.03%
251 $66,000
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $8,694 - $10,135
42 Added 15.67%
310 $67,000
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $27,118 - $36,167
131 Added 95.62%
268 $63,000
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $15,083 - $17,882
59 Added 75.64%
137 $37,000
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $17,587 - $23,072
78 New
78 $23,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Carolinas Wealth Consulting LLC Portfolio

Follow Carolinas Wealth Consulting LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carolinas Wealth Consulting LLC, based on Form 13F filings with the SEC.

News

Stay updated on Carolinas Wealth Consulting LLC with notifications on news.